PDF) WTX101 in patients newly diagnosed with Wilson disease: final
Por um escritor misterioso
Descrição
PDF) Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
PDF) Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series
Wilson Disease in Infancy through Adolescence - ScienceDirect
Chelation therapy in liver diseases of childhood: Current status and response
Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
Inorganics, Free Full-Text
Bis-choline tetrathiomolybdate prevents copper-induced blood–brain barrier damage
Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study - The Lancet Gastroenterology & Hepatology
Current and Emerging Issues in Wilson's Disease
Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease
Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease
PDF) Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment
PDF) Wilson disease
PDF) Benefits and drawbacks of current copper chelators in Wilson disease
PDF) Advances in Treatment of Wilson Disease
